Behavioral Pharma, Inc.

La Jolla, CA 92037

SBIR Award Summary

Total Number of Awards 4
Total Value of Awards $1.03MM
First Award Date 05/01/06
Most Recent Award Date 09/01/11

Key Personnel

Last Name Name Awards Contact
Cashman John R Cashman 1
Azar Marc Reza Azar 3

4 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/11 - 08/31/13

DESCRIPTION (provided by applicant): In the US, alcoholism is a serious disorder that will affect 14% of the population at some point in their lives. 100,000 US citizens will die of alcoholism each year from direct and indirect causes at a cost of $166 billion per year. In addition to contributing to traumatic death and injury (e.g., through car...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 08/31/11

DESCRIPTION (provided by applicant): In the US, alcoholism is a serious disorder that will affect 14% of the population at some point in their lives. 100,000 US citizens will die of alcoholism each year from direct and indirect causes at a cost of $166 billion per year. In addition to contributing to traumatic death and injury (e.g., through car...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/15/09 - 08/31/10

DESCRIPTION (provided by applicant): In the US, alcoholism is a serious disorder that will affect 14% of the population at some point in their lives. 100,000 US citizens will die of alcoholism each year from direct and indirect causes at a cost of $166 billion per year. In addition to contributing to traumatic death and injury (e.g., through car...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/06 - 04/30/09

DESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently appr...